48 filings
EFFECT
MLYS
Mineralys Therapeutics Inc
12 Apr 24
Notice of effectiveness
12:15am
424B5
MLYS
Mineralys Therapeutics Inc
11 Apr 24
Prospectus supplement for primary offering
4:35pm
ARS
2023 FY
MLYS
Mineralys Therapeutics Inc
9 Apr 24
Annual report to shareholders
7:21am
DEFA14A
MLYS
Mineralys Therapeutics Inc
9 Apr 24
Additional proxy soliciting materials
7:18am
DEF 14A
MLYS
Mineralys Therapeutics Inc
9 Apr 24
Definitive proxy
7:15am
8-K
kwmjoq
4 Apr 24
Departure of Directors or Certain Officers
8:04am
S-3/A
45u31
29 Mar 24
Shelf registration (amended)
4:44pm
8-K
1xbisu6dns17i1v
21 Mar 24
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
7:43am
S-3
bgiutbg7di7 hm
21 Mar 24
Shelf registration
7:30am
8-K
ombwsfo38p0p6
8 Feb 24
Mineralys Therapeutics Announces $120 Million Private Placement Financing
4:41pm
8-K
293x rf51s0p
4 Jan 24
Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer
4:10pm
8-K
rxl4n4
22 Dec 23
Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
9:04am
8-K
qx134f o2sl9e8h
13 Nov 23
Regulation FD Disclosure
8:20am
8-K
mqoq9ig 7qa
7 Nov 23
Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:07pm
8-K
l6r39d
2 Nov 23
Regulation FD Disclosure
10:06am
8-K
9f2janyf0h9e eii5ql
14 Sep 23
Departure of Directors or Certain Officers
4:11pm
8-K
wq8hd
7 Aug 23
Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:08pm